Aldeyra Therapeutics Company Profile (NASDAQ:ALDX)

Analyst Ratings

Consensus Ratings for Aldeyra Therapeutics (NASDAQ:ALDX) (?)
Ratings Breakdown: 5 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $14.80 (140.65% upside)

Analysts' Ratings History for Aldeyra Therapeutics (NASDAQ:ALDX)
Show:
DateFirmActionRatingPrice TargetActions
7/1/2016Stifel NicolausInitiated CoverageBuy$16.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/10/2016Cowen and CompanyReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/29/2016Janney Montgomery ScottReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/13/2015Canaccord GenuityReiterated RatingBuy$15.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/13/2015HC WainwrightLower Price TargetBuy$14.00 -> $13.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/25/2015Chardan CapitalInitiated CoverageBuy$16.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/26/2015LaidlawInitiated CoverageBuy$30.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/3/2014Ascendiant Capital MarketsInitiated CoverageBuy$16.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/30/2014 forward)

Earnings

Earnings History for Aldeyra Therapeutics (NASDAQ:ALDX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/9/2016        
5/9/2016Q116($0.50)($0.51)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/30/2016Q415($0.32)($0.46)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/12/2015Q315($0.29)($0.35)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/11/2015Q215($0.35)($0.27)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/13/2015Q115($0.39)($0.32)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/14/2015($0.39)($0.31)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/19/2015($0.40)($0.30)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/10/2014Q314($0.32)($0.36)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/4/2014Q214($0.53)($1.56)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Aldeyra Therapeutics (NASDAQ:ALDX)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Aldeyra Therapeutics (NASDAQ:ALDX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Aldeyra Therapeutics (NASDAQ:ALDX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
5/26/2016Perceptive Advisors LlcMajor ShareholderBuy700,000$5.00$3,500,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/26/2015Perceptive Advisors LlcMajor ShareholderBuy50,000$6.46$323,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/22/2015Perceptive Advisors LlcMajor ShareholderBuy18,020$6.47$116,589.40View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/20/2015Perceptive Advisors LlcMajor ShareholderBuy37,145$6.39$237,356.55View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/7/2014Martin Joseph JoyceDirectorBuy1,000$3.95$3,950.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/6/2014C. Boyd ClarkeDirectorBuy3,000$3.69$11,070.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/7/2014C. Boyd ClarkeDirectorBuy12,500$8.00$100,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Aldeyra Therapeutics (NASDAQ:ALDX)
DateHeadline
07/29/16 02:26 PMSpring Bank Pharmaceuticals : Appoints Dr. Todd C. Brady to its Board of Directors
07/28/16 03:18 PMSpring Bank Pharmaceuticals Appoints Dr. Todd C. Brady to its Board of Directors - [at noodls] - MILFORD, Mass., July 28, 2016 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq:SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, ...
07/23/16 06:52 AMEquity Roundup: Stock Performance Focus on Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) - Press Telegraph
07/21/16 02:27 PMInvestor Update: Earnings and Target Price Recap on Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) - Press Telegraph
07/20/16 09:53 PMAldeyra Therapeutics, Inc. (NASDAQ:ALDX): Sell-Side Ratings and Company Earnings Glance - Engelwood Daily
07/19/16 02:24 PMAldeyra Therapeutics (NASDAQ:ALDX) Institutional Investors Sentiment Index Up in 2016 Q1 - Consumer Eagle
07/19/16 02:24 PMNew Broker Ratings For Aldeyra Therapeutics, Inc. (ALDX) - FTSE News
07/18/16 02:28 PMAldeyra Therapeutics, Inc. (NASDAQ:ALDX) Wall Street Analyst Recommendation Outlook - TGP
07/18/16 07:15 AMHow Analysts Feel About Aldeyra Therapeutics Inc (NASDAQ:ALDX)? - Consumer Eagle
07/17/16 07:09 AMShares Moving Down on the Week: Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) - Engelwood Daily
07/16/16 02:23 PMShares Experiencing a Downtrend: Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) - TGP
07/16/16 02:23 PMAldeyra Therapeutics Incorporated (NASDAQ:ALDX) Short Interest Increased By 3.96% - Consumer Eagle
07/14/16 11:20 AMEye on Stock Volatility for: Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) - Engelwood Daily
07/13/16 02:28 PMAldeyra Therapeutics, Inc. (NASDAQ:ALDX) Earnings Concentration and Analyst Target Watch - Engelwood Daily
07/13/16 02:28 PMAldeyra Therapeutics Incorporated (NASDAQ:ALDX) Shorted Shares Increased By 3.96% - Consumer Eagle
07/12/16 02:27 PMTrading Update - Stock Heading Down in Session: Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) - Telanagana Press
07/12/16 02:27 PMSession Volatility Review for: Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) - Engelwood Daily
07/12/16 07:33 AMWall Street Ratings and Target Price Views on Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) - Telanagana Press
07/10/16 02:23 PMAldeyra Therapeutics Incorporated (NASDAQ:ALDX) Sellers Increased By 3.96% Their Shorts - Engelwood Daily
07/07/16 07:42 PMStock Moving Up in Trading: Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) - Telanagana Press
07/06/16 02:24 PMCan Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) Improve on the Earnings Front? - Engelwood Daily
07/06/16 02:24 PMBroker Outlook For Aldeyra Therapeutics, Inc. (ALDX) - Fiscal Standard
07/04/16 07:12 AMAldeyra Therapeutics, Inc. (ALDX) Broker Price Targets For The Coming Week - Fiscal Standard
07/03/16 07:12 AMWhat's Next for Aldeyra Therapeutics Inc After Today's Huge Increase? - Press Telegraph
07/02/16 10:06 AMThe Market in 5 Minutes: Tesla, Chipotle battling some bad news
07/01/16 02:25 PMHealthcare ratings - new coverage #2 - Seeking Alpha
07/01/16 02:25 PMTracking Stock Volatility for: Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) - Engelwood Daily
07/01/16 02:25 PMShares Headed Up in Session: Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) - Telanagana Press
07/01/16 12:57 PM12 Biggest Mid-Day Gainers For Friday -   Stone Energy Corporation (NYSE: SGY) shares surged 16.7 percent to $14.07. Stone Energy shares have dropped 88.55 percent over the past 52 weeks, while the S&P 500 index has gained 1.45 percent in the same period. Aldeyra Therapeutics Inc (NASDAQ: ALDX) shares jumped 12.7 percent to $6.41. Stifel Nicolaus initiated coverage of Aldeyra Therapeutics with a Buy rating. AEterna Zentaris Inc. (USA) (NASDAQ: AEZS) shares climbed 12.3 percent to $3.66 as the company reported that it has signed an exclusive license agreement with Cyntec, an affiliate of Orient EuroPharma Co, for Zoptrex. Kinross Gold Corporation (USA) (NYSE: Full story available on Benzinga.com
07/01/16 05:59 AMCoverage initiated on Aldeyra Therapeutics by Stifel -
06/30/16 02:26 PMAldeyra Therapeutics, Inc. (ALDX) Current Analyst Ratings - Fiscal Standard
06/28/16 02:39 PMNext Weeks Broker Price Targets For Aldeyra Therapeutics, Inc. (ALDX) - Fiscal Standard
06/28/16 02:39 PMCovering the Bases on Aldeyra Therapeutics, Inc. (NASDAQ:ALDX): Where is the Stock Going? - Press Telegraph
06/10/16 04:04 PMAldeyra Therapeutics, Inc. :ALDX-US: Earnings Analysis: Q1, 2016 By the Numbers : June 10, 2016 -
06/10/16 03:07 PMALDEYRA THERAPEUTICS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders -
06/07/16 07:08 AMAldeyra Therapeutics, Inc. Announces Last Patient Dosed in Phase II Clinical Trial of Topical Dermatologic NS2 in Patients With Sjögren-Larsson Syndrome - [at noodls] - LEXINGTON, MA -- (Marketwired) -- 06/07/16 -- Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to aldehydes, ...
06/02/16 08:22 PMExclusive: Aldeyra CEO Todd Brady Talks Drug Potential, Cash & New Talent - Aldeyra Therapeutics Inc (NASDAQ: ALDX) is a micro-cap biotech company that specializes in the development of drugs for the treatment of immune and inflammatory diseases. Its most advanced drug is an eye drop treatment for Sjogren-Larsson Syndrome.
06/01/16 03:15 PMAldeyra Therapeutics, Inc. Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriter Overallotment Option - [at noodls] - LEXINGTON, MA -- (Marketwired) -- 06/01/16 -- Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to aldehydes, ...
05/29/16 11:25 AMWere Analysts Bullish Aldeyra Therapeutics Inc (NASDAQ:ALDX) This Week? - HNN - Were Analysts Bullish Aldeyra Therapeutics Inc (NASDAQ:ALDX) This Week?HNNOut of 5 analysts covering Aldeyra Therapeutics Inc (NASDAQ:ALDX), 5 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Aldeyra Therapeutics Inc has been the topic of 2 analyst reports since August 13, 2015 according to ...and more »
05/27/16 11:43 AMEarnings Review and Stock Rundown for Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) - Wall Street Hints and News - Earnings Review and Stock Rundown for Aldeyra Therapeutics, Inc. (NASDAQ:ALDX)Wall Street Hints and NewsInvestors and analysts will be paying close attention when the company posts earnings results. Earnings numbers can provide insight into a company's overall profitability. Covering equity analysts are expecting Aldeyra Therapeutics, Inc. (NASDAQ:ALDX ...and more »
05/27/16 11:43 AMGaps Down Stocks Update 1 – CSBR, SMT, ALDX, BRS, OVAS, TDW, PSTG - The company traded at $4.49 – 0.46 (9.29 pct). Aldeyra Therapeutics Inc (ALDX) had a gap down of (0.50) pts or -8.96 pct below its previous close of $5.58. The company traded at $5.03 – 0.55 (9.86 pct). Bristow Group Inc (BRS) had a gap down of (2.19 ...
05/27/16 11:43 AMALDX Prices Offering At $5.00/Share - (RTTNews.com) - Aldeyra Therapeutics Inc. ( ALDX) has offered to sell 2.4 million shares of its common stock to the public at a price of $5.00 each. The gross proceeds from the offering are expected to be $12.0 million. The company had cash of $23.0 ...
05/27/16 05:15 AMALDEYRA THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial St -
05/26/16 10:46 AMAldeyra Therapeutics, Inc. (ALDX) Updated Price Targets - FTSE News - Aldeyra Therapeutics, Inc. (ALDX) Updated Price TargetsFTSE News08/13/2015 – Aldeyra Therapeutics, Inc. had its “buy” rating reiterated by analysts at H.C. Wainwright. They now have a USD 13 price target on the stock. 03/25/2015 – Chardan Capital began new coverage on Aldeyra Therapeutics, Inc. giving the company a ...
05/26/16 10:46 AMAldeyra Therapeutics (ALDX) Prices 2.4M Common Stock Offering at $5/Share - StreetInsider.com - Aldeyra Therapeutics (ALDX) Prices 2.4M Common Stock Offering at $5/ShareStreetInsider.comAldeyra Therapeutics, Inc. (Nasdaq: ALDX) announced the pricing of an underwritten public offering of 2,400,000 shares of its common stock at a price to the public of $5.00 per share. The gross proceeds from the offering are expected to be $12.0 ...Aldeyra Therapeutics Plans to Offer Shares in Underwritten Public Offering (NASDAQ:ALDX)Sonoran Weekly ReviewAldeyra Therapeutics Inc (NASDAQ:ALDX)'s Company Shares Decreased 8.37% After Low VolatilityWall Street Hints and NewsAldeyra Therapeutics, Inc. Proposes Public Offering of Common StockEIN News (press release)all 4 news articles »
05/26/16 10:46 AMAfter-Hours Stock Movers 05/25: (LGF) (PVH) (WSM) Higher; (PRGN) (PSTG) (ALDX) Lower (more...) - Revenue for the quarter came in at $791.2 million versus the consensus estimate of $740.67 million. Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) 10.2% LOWER; intends to offer and sell shares of its common stock in an underwritten public offering. The offering ...
05/09/16 06:46 AMAldeyra Therapeutics Announces Positive Results From Phase II Clinical Trial in Subjects With Noninfectious Anterior Uveitis - [at noodls] - LEXINGTON, MA -- (Marketwired) -- 05/09/16 -- Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to aldehydes, ...
05/05/16 03:14 PMAldeyra Therapeutics Schedules Webcast and Conference Call for First Quarter 2016 Financial and Operating Updates - [Marketwired] - Aldeyra Therapeutics, Inc. , a biotechnology company focused on the development of products to treat diseases related to aldehydes, today announced that it will issue its financial results for the first ...
03/31/16 06:33 AMALDEYRA THERAPEUTICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits -
03/30/16 08:44 AMEdited Transcript of ALDX earnings conference call or presentation 30-Mar-16 12:30pm GMT -

Social

About Aldeyra Therapeutics

Aldeyra Therapeutics logoAldeyra Therapeutics, Inc., formerly Aldexa Therapeutics, Inc., is a biotechnology company. The Company is focused primarily on the development of new products for immune-mediated, inflammatory, orphan and other diseases that are caused by naturally occurring toxic chemical species known as free aldehydes. The Company has developed a series of product candidates that are designed specifically to trap and allow for the degradation of free aldehydes. The Company's most advanced product candidate is an eye drop formulation of NS2, which is under development for the treatment of Sjogren-Larsson Syndrome (SLS). The Company has completed a double-masked, placebo-controlled, Phase I clinical testing of 0.25% and 0.5% NS2 administered as an eye drop for safety and tolerability in approximately 48 healthy volunteers. Data from the Phase I study demonstrated that NS2 was well tolerated in all subjects throughout the duration of the study.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: ALDX
  • CUSIP:
Key Metrics:
  • Previous Close: $6.15
  • 50 Day Moving Average: $5.77
  • 200 Day Moving Average: $5.27
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $38.41M
  • Beta: 0.17
  • Current Year EPS Consensus Estimate: $-1.84 EPS
  • Next Year EPS Consensus Estimate: $-2.14 EPS
Additional Links:
Aldeyra Therapeutics (NASDAQ:ALDX) Chart for Saturday, July, 30, 2016